Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

NIA-funded Alzheimer centers are more efficient than commercial clinical recruitment sites for conducting secondary prevention trials of dementia.

Edland SD, Emond JA, Aisen PS, Petersen RC.

Alzheimer Dis Assoc Disord. 2010 Apr-Jun;24(2):159-64. doi: 10.1097/WAD.0b013e3181c9983f.

2.

Vitamin E and donepezil for the treatment of mild cognitive impairment.

Barnes DE, Yaffe K.

N Engl J Med. 2005 Sep 1;353(9):951-2; author reply 951-2. No abstract available.

3.

Mild cognitive impairment--no benefit from vitamin E, little from donepezil.

Blacker D.

N Engl J Med. 2005 Jun 9;352(23):2439-41. Epub 2005 Apr 13. No abstract available.

PMID:
15829528
4.

Drug treatment for Alzheimer's disease.

Tom T, Cummings JL.

West J Med. 1998 Apr;168(4):264. No abstract available.

5.

Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia.

van Straaten EC, Harvey D, Scheltens P, Barkhof F, Petersen RC, Thal LJ, Jack CR Jr, DeCarli C; Alzheimer's Disease Cooperative Study Group.

J Neurol. 2008 Sep;255(9):1302-8. doi: 10.1007/s00415-008-0874-y. Epub 2008 Sep 25.

6.

Vitamin E and donepezil for the treatment of mild cognitive impairment.

Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ; Alzheimer's Disease Cooperative Study Group.

N Engl J Med. 2005 Jun 9;352(23):2379-88. Epub 2005 Apr 13.

8.

Do we have drugs for dementia? No.

Pryse-Phillips W.

Arch Neurol. 1999 Jun;56(6):735-7. Review. No abstract available.

PMID:
10369315
9.

Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.

Rolinski M, Fox C, Maidment I, McShane R.

Cochrane Database Syst Rev. 2012 Mar 14;3:CD006504. doi: 10.1002/14651858.CD006504.pub2. Review.

PMID:
22419314
10.
11.

Characteristics and performance of a modified version of the ADCS-CGIC CIBIC+ for mild cognitive impairment clinical trials.

Schneider LS, Raman R, Schmitt FA, Doody RS, Insel P, Clark CM, Morris JC, Reisberg B, Petersen RC, Ferris SH.

Alzheimer Dis Assoc Disord. 2009 Jul-Sep;23(3):260-7. doi: 10.1097/WAD.0b013e31819cb760.

12.

Donepezil for severe Alzheimer's disease.

Allsop D, Martin FL, Moore S, Fullwood NJ; Alzheimer's Society.

Lancet. 2006 Jul 29;368(9533):361; author reply 362. No abstract available.

PMID:
16876652
13.

Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.

Farlow M, Potkin S, Koumaras B, Veach J, Mirski D.

Arch Neurol. 2003 Jun;60(6):843-8.

PMID:
12810489
14.

Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment.

Fleisher AS, Sowell BB, Taylor C, Gamst AC, Petersen RC, Thal LJ; Alzheimer's Disease Cooperative Study.

Neurology. 2007 May 8;68(19):1588-95. Epub 2007 Feb 7.

PMID:
17287448
15.

Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy.

Reynolds CF 3rd, Butters MA, Lopez O, Pollock BG, Dew MA, Mulsant BH, Lenze EJ, Holm M, Rogers JC, Mazumdar S, Houck PR, Begley A, Anderson S, Karp JF, Miller MD, Whyte EM, Stack J, Gildengers A, Szanto K, Bensasi S, Kaufer DI, Kamboh MI, DeKosky ST.

Arch Gen Psychiatry. 2011 Jan;68(1):51-60. doi: 10.1001/archgenpsychiatry.2010.184.

16.

A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.

Di Santo SG, Prinelli F, Adorni F, Caltagirone C, Musicco M.

J Alzheimers Dis. 2013;35(2):349-61. doi: 10.3233/JAD-122140. Review.

PMID:
23411693
17.

[Mild Cognitive Impairment: potential therapeutics].

Allain H, Bentue-Ferrer D, Belliard S, Reymann JM, Djemaï M, Merienne M.

Rev Neurol (Paris). 2002;158(10 Suppl):S35-40. Review. French.

PMID:
12529584
18.

Clinical trials in mild cognitive impairment: lessons for the future.

Jelic V, Kivipelto M, Winblad B.

J Neurol Neurosurg Psychiatry. 2006 Apr;77(4):429-38. Epub 2005 Nov 23. Review. Erratum in: J Neurol Neurosurg Psychiatry. 2006 Jul;77(7):892.

19.

Ginkgo biloba for prevention of dementia: a randomized controlled trial.

DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, Lopez OL, Burke G, Carlson MC, Fried LP, Kuller LH, Robbins JA, Tracy RP, Woolard NF, Dunn L, Snitz BE, Nahin RL, Furberg CD; Ginkgo Evaluation of Memory (GEM) Study Investigators.

JAMA. 2008 Nov 19;300(19):2253-62. doi: 10.1001/jama.2008.683. Erratum in: JAMA. 2008 Dec 17;300(23):2730.

20.

Donepezil treatment of older adults with cognitive impairment and depression (DOTCODE study): clinical rationale and design.

Pelton GH, Andrews H, Roose SP, Marcus SM, D'Antonio K, Husn H, Petrella JR, Zannas AS, Doraiswamy PM, Devanand DP.

Contemp Clin Trials. 2014 Mar;37(2):200-8. doi: 10.1016/j.cct.2013.11.015. Epub 2013 Dec 5.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk